Table 1 Clinical characteristics and patient demographics at baseline.

N (%)

16

12 (75)

4(25)

ND

Age (year)

30 ± 11.3

31.8 ± 11.6

25 ± 10.2

0.17

Malen(K)

7 (43.8)

4 (33.3)

3(75)

0.14

Female n {%}

9 (56.3)

a (66.7)

1(25)

ND

BMI

22.1 ± 3.6

22.7 ± 3.5

20.5 ± 3.8

0.33

Complete Mayo score

4.2 ± 2.8

ND

CDAI

272.5 ± 223.9

ND

Disease duration (Month)

45,157

39,8 ± 54.3

63 ± 26.6

0.06

Fecal calprotectin (ug/g)

2031 ± 3140.9

2260.5 ± 3431.9

1001.9 ± 1353.4

0.31

Albumin (g/L)

39 ± 7.9

41.1 ± 4,5

33.1 ± 13.6

0.26

CRP(mg/L)

11.3tl7.5

7.2 ± 6

32.7 ± 35.5

0.15

Hemoglobin (g/L)

11.8 ± 2.6

11.8 ± 2

10.4 ± 4.1

0.29

Naive (%)

14 (87.5)

12 (100)

2(50)

0.01

Pervious failure to Anti-TNF (%)

2 (12.5)

0 (0.0)

2(50)

ND

Concomitant immunomodulator (%]

3 (18.S)

3(25)

0 (0.0)

0.16

Concomitant steroid (%)

5(31.3)

4(33.3)

1(25)

0.75